echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: TIGIT antibody Etigilimab ± nivolumab in the treatment of advanced solid tumors

    Clin Cancer Res: TIGIT antibody Etigilimab ± nivolumab in the treatment of advanced solid tumors

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TIGIT is a co-inhibitory receptor for T cell and natural killer cell activity


    immunity

    This is the first open-label, multi-center, dose-escalation, and expanded phase 1a/b clinical trial in humans, recruiting patients with locally advanced or metastatic solid tumors


    Treatment-related side effects

    Treatment-related side effects

    A total of 33 patients were recruited (23 in stage 1a and 10 in stage 1b)


    Treatment response of different tumors

    Treatment response of different tumors

    In stage 1a, 7 patients (30.


    In stage 1a, 7 patients (30.


    All in all, Etigilimab has acceptable safety.


    Etigilimab has acceptable safety.


    Original source:

    Niharika B.


    A Phase 1a / b Open? Label , Dose? Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.